AU2007211655A1 - Methods for interfering with glucocorticoid induced gastric acid secretion - Google Patents

Methods for interfering with glucocorticoid induced gastric acid secretion Download PDF

Info

Publication number
AU2007211655A1
AU2007211655A1 AU2007211655A AU2007211655A AU2007211655A1 AU 2007211655 A1 AU2007211655 A1 AU 2007211655A1 AU 2007211655 A AU2007211655 A AU 2007211655A AU 2007211655 A AU2007211655 A AU 2007211655A AU 2007211655 A1 AU2007211655 A1 AU 2007211655A1
Authority
AU
Australia
Prior art keywords
phenyl
hydroxy
methoxy
hydrazid
benzyliden
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007211655A
Other languages
English (en)
Inventor
Florian Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2007211655A1 publication Critical patent/AU2007211655A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2007211655A 2006-01-31 2007-01-17 Methods for interfering with glucocorticoid induced gastric acid secretion Abandoned AU2007211655A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06001934 2006-01-31
EP06001934.6 2006-01-31
PCT/EP2007/000350 WO2007087985A1 (fr) 2006-01-31 2007-01-17 Procédé permettant d'interférer avec la sécrétion d'acide gastrique induite par glucocorticoïde

Publications (1)

Publication Number Publication Date
AU2007211655A1 true AU2007211655A1 (en) 2007-08-09

Family

ID=38006823

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007211655A Abandoned AU2007211655A1 (en) 2006-01-31 2007-01-17 Methods for interfering with glucocorticoid induced gastric acid secretion

Country Status (7)

Country Link
EP (1) EP1979747A1 (fr)
JP (1) JP2009531020A (fr)
AR (1) AR059258A1 (fr)
AU (1) AU2007211655A1 (fr)
CA (1) CA2641325A1 (fr)
IL (1) IL193081A0 (fr)
WO (1) WO2007087985A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210008193A (ko) * 2019-07-10 2021-01-21 한양대학교 산학협력단 염증성 신경 질환의 치료제로서 Sgk1 저해제의 용도
US20240024333A1 (en) * 2020-10-26 2024-01-25 Regents Of The University Of Minnesota Use of small molecule fak activators to promote mucosal healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10346913A1 (de) * 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
US20070191325A1 (en) * 2004-03-08 2007-08-16 Florian Lang Methods for altering insulin secretion
KR20070015148A (ko) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 혈청 및 글루코코르티코이드 유도가능한 키나아제의조절제의 용도를 포함하는 신경정신학적 장애를 치료하기위한 글루탐산 수용체의 조절 방법
CN1964705A (zh) * 2004-03-11 2007-05-16 默克专利有限公司 干扰纤维化的方法
US20090136920A1 (en) * 2004-04-30 2009-05-28 Stefan Golz Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)

Also Published As

Publication number Publication date
WO2007087985A1 (fr) 2007-08-09
EP1979747A1 (fr) 2008-10-15
JP2009531020A (ja) 2009-09-03
IL193081A0 (en) 2009-02-11
AR059258A1 (es) 2008-03-19
CA2641325A1 (fr) 2007-08-09

Similar Documents

Publication Publication Date Title
Bouchard Genetics of obesity: what we have learned over decades of research
Turan et al. GNAS spectrum of disorders
Valverde et al. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes
Ren et al. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis
Akune et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts
US20080146540A1 (en) Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association
Schwab et al. Association of SGK1 gene polymorphisms with type 2 diabetes
US20120149016A1 (en) Genetic Variants in the TCF7L2 Gene as Diagnostic Markers for Risk of Type 2 Diabetes Mellitus
Abou Ziki et al. The interplay of canonical and noncanonical Wnt signaling in metabolic syndrome
Hu et al. Isoform-specific functions of PPARγ in gene regulation and metabolism
Herdenberg et al. LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes
Ghanaat-Pour et al. Global expression profiling of glucose-regulated genes in pancreatic islets of spontaneously diabetic Goto-Kakizaki rats
AU2007211655A1 (en) Methods for interfering with glucocorticoid induced gastric acid secretion
Sandu et al. Role of the serum and glucocorticoid inducible kinase SGK1 in glucocorticoid stimulation of gastric acid secretion
WO2005108613A9 (fr) Proteine d'interaction de voies du gene kv (kchip1) de diabete humain de type ii situee sur le chromosome 5
CA2487730A1 (fr) Sgk et nedd utilises comme cibles diagnostiques et therapeutiques
KR20050114214A (ko) 백내장 및 녹내장을 진단 및 치료하기 위한 ｓｇｋ 유전자패밀리의 용도
Hu et al. The association between transforming growth factor β3 polymorphisms and left ventricular structure in hypertensive subjects
Gao et al. Polymorphism of DsbA-L gene associates with insulin secretion and body fat distribution in Chinese population
ZA200608355B (en) Methods for altering insulin secretion
JP3842130B2 (ja) Ｍａｐキナーゼ経路を活性化するホスファターゼ
Müller et al. SNP dependent modulation of circulating miRNAs from the miR25/93/106 cluster in patients undergoing weight loss
US8067158B2 (en) Methods and compositions for the diagnosis and treatment of schizophrenia
JP4997547B2 (ja) 炎症性疾患の判定方法
WO2007121963A1 (fr) Méthodes pour soulager une maladie liée à une activation affaiblie de mastocytes

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period